Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
MOUNTAIN VIEW, Calif., Nov. 12, 2015 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company developing orally-administered therapeutics to treat autoimmune...
-
-- All patients complete dosing in complement inhibitor CCX168 program for ANCA Associated Vasculitis; Phase II CLEAR clinical trial top-line results anticipated in December or early January -- --...
-
Phase II diabetic nephropathy trial results showing improvements in proteinuria over 52 weeks of treatment, sustained effect in follow-up period after drug withdrawal; potential renoprotective,...
-
-- In pancreatic cancer patient trial, excellent receptor blockade achieved with chemokine receptor CCR2 inhibitor CCX872, bodes well for ongoing multi-dose part of clinical trial; Patient...
-
MOUNTAIN VIEW, Calif., Oct. 29, 2015 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq:CCXI),a clinical-stage biopharmaceutical developing orally-administered therapeutics to treat autoimmune diseases,...
-
MOUNTAIN VIEW, Calif., Sept. 2, 2015 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company focused on autoimmune diseases, inflammatory disorders and...
-
- Completed enrollment in the European Vasculitis Phase II CLEAR trial of C5aR inhibitor CCX168; top line data expected by year-end 2015 - - North American Vasculitis Phase II CLASSIC trial of...
-
MOUNTAIN VIEW, Calif., July 30, 2015 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company focused on autoimmune diseases, inflammatory disorders and...
-
MOUNTAIN VIEW, Calif., July 29, 2015 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq:CCXI), a clinical-stage biopharmaceutical company focused on autoimmune diseases, inflammatory disorders and cancer,...
-
-- Significant reduction in proteinuria over 52 weeks of treatment suggests CCX140 may have renoprotective effects exceeding current standard of care alone -- -- Separately, poster describing...